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Abstract
Background: Private for-profit outlets are important treatment sources for malaria in most endemic countries. However,
these outlets constitute only the last link in a chain of businesses that includes manufacturers, importers and wholesalers, all
of which influence the availability, price and quality of antimalarials patients can access. We present evidence on the
composition, characteristics and operation of these distribution chains and of the businesses that comprise them in six
endemic countries (Benin, Cambodia, Democratic Republic of Congo, Nigeria, Uganda and Zambia).
Methods and Findings: We conducted nationally representative surveys of antimalarial wholesalers during 2009–2010
using an innovative sampling approach that captured registered and unregistered distribution channels, complemented by
in-depth interviews with a range of stakeholders. Antimalarial distribution chains were pyramidal in shape, with
antimalarials passing through a maximum of 4–6 steps between manufacturer and retailer; however, most likely pass
through 2–3 steps. Less efficacious non-artemisinin therapies (e.g. chloroquine) dominated weekly sales volumes among
African wholesalers, while volumes for more efficacious artemisinin-based combination therapies (ACTs) were many times
smaller. ACT sales predominated only in Cambodia. In all countries, consumer demand was the principal consideration
when selecting products to stock. Selling prices and reputation were key considerations regarding supplier choice. Business
practices varied across countries, with large differences in the proportions of wholesalers offering credit and delivery
services to customers, and the types of distribution models adopted by businesses. Regulatory compliance also varied
across countries, particularly with respect to licensing. The proportion of wholesalers possessing any up-to-date licence
from national regulators was lowest in Benin and Nigeria, where vendors in traditional markets are important antimalarial
supply sources.
Conclusions: The structure and characteristics of antimalarial distribution chains vary across countries; therefore,
understanding the wholesalers that comprise them should inform efforts aiming to improve access to quality treatment
through the private sector.
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Introduction
In most low- and middle-income countries, the private for-profit
sector is an important source of health care, with providers
ranging from health facilities staffed by physicians and nurses, to
pharmacies overseen by registered pharmacists, to more general
types of retailers, including market stall and itinerant vendors,
often with little or no formal health-related training [1–3]. These
varied outlets constitute just the last link in a chain of businesses,
which includes manufacturers, importers and wholesalers, which
have an important influence on the availability, price and quality
of medicines and other health-related commodities at the retail
level [4].
The private sector is particularly important for the treatment of
malaria [4–16]. Although malaria treatment is typically provided
for free or highly subsidised in the public sector, in many countries
private sector outlets are often the first and only source of
treatment used outside the home [17,18]. Here, consumers face a
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wide array of treatment choices, including artemisinin-based
combination therapies (ACTs), which are the most efficacious drug
regimens and the official first-line treatments in most endemic
countries; non-artemisinin therapies (nATs) such as chloroquine,
quinine, and sulphadoxine-pyrimethamine (SP), many of which
were recommended treatments before the ACT era and the rise of
parasite resistance; and artemisinin monotherapies (AMTs). Due
to the risk that the irrational use of AMT poses for the
development of artemisinin resistance, many countries have
banned private sector sales of AMTs in oral dosage forms.
A wealth of information on private sector antimalarial supply
and demand is now available from several endemic countries
through ACTwatch, a five-year multi-country research project
(www.actwatch.info). ACTwatch household surveys between 2008
and 2010 found that private for-profit sector patients were less
likely to undergo malaria diagnostic testing and to receive ACTs,
and were more likely to purchase nATs and other medicines [17].
This was corroborated by ACTwatch retail outlet surveys in 2009
and 2010. Among private for-profit outlets stocking at least one
antimalarial in the six African study countries, availability of the
recommended quality-assured (i.e. appear on WHO or UNICEF
procurement lists) first-line ACTs ranged from 6% to 25%, while
nearly 100% stocked nATs; they had a median price 5 to 23 times
more expensive than the most popular nAT alternative; and their
sales volumes represented less than 6% of the total antimalarial
market share [19]. This is in contrast with the situation observed in
Cambodia, where ACTs have been subsidised and socially
marketed by Population Services International in the private
sector since 2004 [20]: subsidised ACTs were available among
58% of private outlets stocking any antimalarial and accounted for
nearly half of the antimalarial volumes sold through the private
sector [18].
However, rigorous supply-side evidence that examines the
structure and operation of the antimalarial distribution chain
serving these private outlets is limited. A 2010 review identified key
gaps as a lack of nationally representative studies on antimalarial
distribution chains; limited information on the number and
characteristics of antimalarial suppliers, their sales volumes and
mark-ups, particularly on unregistered suppliers; and an absence
of rigorous analysis of the factors influencing ACT availability and
prices [4]. The third ACTwatch component, the supply chain
study, aimed to address these gaps by conducting quantitative and
qualitative studies on distribution chains for antimalarials. This
paper presents novel evidence derived from nationally represen-
tative surveys and in-depth interviews on the structure and
composition of antimalarial distribution chains, wholesaler busi-
ness practices, and pharmaceutical sector regulation in six
countries (Benin, Cambodia, the Democratic Republic of Congo
(DRC), Nigeria, Uganda and Zambia).
Methods
Ethical Considerations
Experience from other ACTwatch studies conducted in the
same locations demanding similar levels of participation found that
written consent was often unacceptable to private sector respon-
dents, who sometimes perceived providing signatures as potentially
incriminating with regulatory bodies given the sensitive nature of
the topics being covered. For others, insisting on written consent
was found to cause confusion about the study purpose and distress
participants. The use of verbal consent and the study as a whole
was approved by the London School of Hygiene & Tropical
Medicine Ethics Committee (No. 5466, 18 February 2009) and by
ethical review boards in each country: the Comite´ national
provisoire d’e´thique pour la recherche en sante´ of Benin; the
Cambodian National Ethics Committee for Health Research; the
Comite´ d’E´thique de l’E´cole de Sante´ Publique de l’Universite´ de
Kinshasa; the National Health Research Ethics Committee of
Nigeria; the Research & Ethics Committee of the Makerere
University Faculty of Medicine; and the University of Zambia
Biomedical Research Ethics Committee. All potential respondents
were given an information sheet in English, French or Khmer (in
Cambodia), which emphasised the confidentiality of the informa-
tion being collected, and if verbal consent was obtained, the
interviewer attested to such by completing a signed certificate of
consent.
Country Contexts (Table 1)
The ACTwatch study countries were selected to provide a
diverse range of markets from which comparisons and contrasts
could be made. Consideration was given to several factors,
including malaria burden, size of the population at risk, the scope
and nature of pharmaceutical regulation (e.g. high vs. low;
Francophone vs. Anglophone), public sector capacity and cover-
age, domestic antimalarial manufacturing capacity, existing
antimalarial subsidy interventions and the feasibility of receiving
the necessary country level authorisation to conduct the research
[21].
In all the African study countries Plasmodium falciparum (Pf) is the
dominant malaria species, and over 90% of the population live in
areas of high transmission. In Cambodia, 44% of the population
lives in high transmission areas and infections with Plasmodium vivax
(Pv) account for over a third of malaria cases [22]. At the time of
data collection in 2009–2010, all study countries had already
adopted ACT as the first-line treatment for uncomplicated
malaria, and banned the distribution of AMT in oral dosage
forms. In addition, national treatment policies were changed to
recommend that patients with suspected malaria undergo a
diagnostic test using either microscopy or rapid diagnostic tests
(RDT). Although, treatment based on a clinical diagnosis was still
recommended for suspected cases in children less than five years of
age in Benin, Nigeria and Uganda; and in the DRC testing was
only prescribed in cases of treatment failure or complicated
malaria.
Licensing regulations for private businesses vary somewhat
across countries. In the African study countries, there are separate
licences for operating wholesale and retail pharmacies, both of
which permit the sale of all registered pharmaceutical products
and require businesses to be staffed by a supervising registered
pharmacist. In Cambodia, there are three types of pharmaceutical
business licenses permitting the sale of all registered pharmaceu-
ticals: ‘pharmacies’ sell on both a wholesale and retail basis, and
are managed by a registered pharmacist; retail-only ‘depot A’ and
‘depot B’ businesses are managed by an assistant pharmacist or a
retired public health staff member with a minimum qualification
of nurse or midwife, respectively [23]. In all countries except
Cambodia and the DRC, licences are also issued to operate
smaller retail businesses that are permitted to sell a limited range of
over-the-counter (OTC) medicines. Often known as drug shops (or
Proprietary Patent Medicine Vendors, PPMVs, in Nigeria), these
retailers are not operated by registered pharmacists.
Quantitative Methods
Sampling for the ACTwatch supply chain study drew on the
nationally representative ACTwatch surveys of antimalarial retail
outlets [18,19]. During these surveys, all eligible outlets were asked
to provide contact information for their top two antimalarial
suppliers; and each instance a supplier was identified in this way
Private Sector Antimalarial Distribution Chains
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was termed a ‘mention’. Supplier mentions collected from private
sector outlets and any mentions from public sector outlets
identifying private sector suppliers were used to create the
sampling frame for the first level of wholesalers, called ‘terminal
wholesaler’ (i.e. wholesalers supplying outlets). In smaller coun-
tries, all supplier mentions from the ACTwatch outlet survey
sample were used to create the terminal-level sampling frame,
while in larger countries supplier mentions from only a sub-sample
of outlets were used (Table 2). We attempted to interview all
wholesalers identified on the sampling frame. This process was
repeated with all terminal wholesalers interviewed to identify
businesses operating one level higher in the distribution chain (i.e.
‘intermediate-1 wholesalers’), and yet again (i.e. ‘intermediate-2
wholesalers, etc.) until only importers or manufacturers were
identified as supply sources. At this point, the top of the
distribution chain was deemed to have been reached. This
‘bottom-up’ sampling approach facilitated the identification of
all types of wholesale suppliers, including those that might
otherwise be excluded because they do not possess the appropriate
licence from the regulatory authority (e.g. unlicensed businesses,
licensed retailers that wholesale).
In Benin and Nigeria, traditional markets that are common
throughout West Africa are important sources of antimalarial
wholesaling, posing several challenges to sampling and data
collection. Because some market-based respondents were reluctant
to be interviewed due to political and regulatory sensitivities
surrounding medicine-selling in markets, attempts were made to
replace any refusals with respondents from similar businesses
operating within the same market. Also, because markets do not all
operate every day of the week, it was not possible to survey market
wholesalers in each of the identified market towns, in which case
wholesalers were sampled from markets in nearby towns to
represent them. While market-based supply sources were typically
mentioned only by retailers in Nigeria, both retailers and
wholesalers in Benin commonly said they purchased antimalarials
from markets sources, often without naming a specific vendor and
giving only the market name. As such, it was difficult to ascertain
which and how many wholesalers needed to be sampled in each of
the identified markets in Benin, potentially leading to over- or
under-sampling of market wholesalers. In the absence of a
sampling frame for unlicensed market wholesalers in Benin, we
used the frequency of market supplier mentions relative to the total
number of supplier mentions from the quantitative survey to
approximate the distribution of market-based wholesalers across
all identified markets in Benin and also to calculate pseudo-
probability weights, which were used to adjust results to account
for over- or under-sampling of market wholesalers and applied in
Stata v.11 and v.12 [24,25] using a variety of commands that
support the aweight and pweight options (see supporting information
Text S1 for details on sampling in markets and the calculation of
weighted summary measures). Summary measures for Nigeria
were not weighted because, unlike in Benin, most market-based
supplier mentions named specific businesses and were gathered
predominantly from retailers. As the number of market-based
wholesalers to be interviewed in various locations in Nigeria was
much clearer, the risk of over- and under-sampling was minimal.
In addition, summary measures for the remaining countries were
not weighted because all wholesalers could be identified from the
supplier mention information collected from respondents.
All identified wholesalers that could be located were screened
for eligibility, with the full questionnaire administered if they had
either an antimalarial or RDT in stock at the time of interview, or
they reported having stocked either antimalarials or RDTs in the
three months prior to interview. In each business, trained local
interviewers sought to speak with the person most knowledgeable
about their antimalarial wholesale business.
Data collection tools were piloted and adapted for each country
setting. A structured questionnaire was used to collect data on each
wholesale business’s characteristics and operations and on the
wholesalers’ top two supply sources for antimalarials. Inventory
Table 1. Key characteristics of malaria epidemiology, treatment policy and pharmaceutical licensing by country.
COUNTRY
BENIN CAMBODIA DRC NIGERIA UGANDA ZAMBIA
Predominant malaria parasite
species [22]
P falciparum (100%)P falciparum (63%),
P vivax (37%)
P falciparum
(100%)
P falciparum
(100%)
P falciparum
(100%)
P falciparum
(100%)
% of population living in high
transmission areas ($1 case per
1000 population) [22]
100 44 97 100 90 100
Recommended first-line treatment for
uncomplicated malaria (2010) [22]
AL P falciparum: ASMQ,
DHA-PP-PQ; P vivax:
CQ, DHA-PP*
ASAQ AL, ASAQ AL AL
ACT officially provided free of charge
in public sector
NO YES YES YES YES YES
Licences issued for pharmaceutical
wholesaling
YES: importer+
wholesaler
YES: importer,
wholesaler+ retailer
YES: three types
of wholesaler
YES: importer, two
types of wholesaler
YES: wholesaler YES: importer,
wholesaler
Licences issued for pharmaceutical
retailing
YES: retail
pharmacy
YES: wholesaler+ retailer,
depot A & B
YES: retail pharmacy,
hospital pharmacy
YES: retail
pharmacy
YES: retail
pharmacy
YES: retail
pharmacy
Licences issued for retailing of only
OTC medicines
YES: rural
outpost pharmacy
NO NO YES: PPMV YES: drug
shop
YES: drug
store
P: Plasmodium; ACT: artemisinin-based combination therapy; AL: artemether-lumefantrine; ASAQ: artesunate-amodiaquine; ASMQ: artesunate-mefloquine; CQ:
chloroquine; DHA-PP-PQ: dihydroartemisinin-piperaquine-primaquine; DHA-PP: dihydroartemisinin-piperaquine; OTC: over-the-counter; PPMV: Proprietary Patent
Medicine Vendors. * As part of the programme to contain the spread of artemisinin resistance, Cambodia’s treatment guidelines until early-2011 recommended the use
of DHA-PP in the highest risk areas (combined with PQ where safe use has been demonstrated) and ASMQ everywhere else to treat P falciparum malaria, and DHA-PP
for the treatment of P vivax malaria since 2011 (CQ was used previously). Since early-2011, Cambodia’s treatment guidelines have recommended the use of DHA-PP
(combined with PQ where safe use has been demonstrated) for both P falciparum and P vivax malaria. [22].
doi:10.1371/journal.pone.0093763.t001
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sheets were used to record each antimalarial stocked, including
brand, generic name, strength, package type and size, recall of
volumes sold over the previous week, recall of last purchase value,
and selling and purchase prices. Data collection for the supply
chain study in each country was timed to follow shortly after the
ACTwatch outlet survey and to coincide as much as possible with
periods of peak malaria transmission (Table 2).
All data were double entered using EpiData v.3.1 and analysed
with Stata v.11 and v.12. Descriptive characteristics of wholesalers
are presented as percentages with 95% confidence intervals or
medians with inter-quartile range. Sales volumes are presented in
terms of adult equivalent treatment doses (AETD), a standardised
unit which allows meaningful comparisons between antimalarials
with different treatment regimens [19,21,26]. Where respondents
could not recall or refused to provide sales volume information,
volumes were imputed using multiple imputation methods based
on the mi impute pmm command in Stata. The supporting
information in Text S2 and footnotes to Table 3 present additional
details on the volumes analysis.
Qualitative Methods
We conducted in-depth interviews with a subset of antimalarial
wholesalers and retailers to further explore a range of topics
related to the structure and composition of the market and
distribution chain; provider conduct (e.g. transport of drugs, credit,
source and cost of capital, marketing techniques, how stocking and
supplier choices are made); and perceptions of the appropriateness
of regulations and the enforcement capacity of authorities. Using
the businesses participating in the quantitative survey as a
sampling frame, interviewees were purposively selected at various
levels of the distribution chain from manufacturers and importers
down to retailers, and across various settings (i.e. urban vs. rural
location; accessible vs. remote market) to capture a diverse range
of experiences, practices and opinions [27]. Similar interviews
were also conducted with key public and private sector stakehold-
ers situated at the top of the distribution chain identified through a
review of relevant documents and consultation with actors familiar
with the country’s antimalarial market. A member of the research
team from the London School of Hygiene & Tropical Medicine
conducted the interviews using a semi-structured interview guide,
which was informed by existing literature and the study’s aims and
objectives. Given the sensitivity of some topics discussed during
these interviews, detailed notes of discussions were taken by a
trained local research assistant, rather than having them recorded
and transcribed. As such, narrative examples rather than verbatim
quotes are used to illustrate or explain themes.
Using a thematic analysis approach [28], all interview notes
were read to identify the main themes or experiences. An initial
coding structure of the main themes was developed based on the
research questions and existing literature, which was then applied
by one team member to interview notes and revised as analysis
proceeded by adding additional codes and sub-codes to capture as
many nuances in the data as possible. To ensure consistency across
countries, co-coding exercises were conducted at the beginning of
the coding process where pairs of researchers independently coded
a minimum of 5 interview transcripts and then compared coding.
Any discrepancies were discussed and agreed between coders [28].
Data from related themes were grouped together and summarised
by noting the frequency and range of terms, concepts, practices or
experiences described by respondents. Differences across distribu-
tion chain levels and countries were noted. Coding and thematic
analysis was conducted using NVivo 8 software. Information from
these in-depth interviews was supplemented with a review of
relevant documents on antimalarial regulation and policy.
Results
Overview of the Sample
Using the ‘bottom-up’ sampling method described above, we
identified 988 antimalarial wholesale sources operating at various
distribution chain levels. Of these, 26 were not eligible to
participate because they did not have antimalarials in stock at
any point during the three month period prior to the survey, 47
refused, 125 were later found to be duplicate mentions or could
not be found, and a further 39 were not interviewed for other
reasons (e.g. a suitable respondent was not available after three
Table 2. Sample breakdown - number of wholesalers identified and interviewed, and antimalarial products audited.
COUNTRY
BENIN CAMBODIA DRC NIGERIA UGANDA ZAMBIA
Dates of data collection 4–29 Jun
2009
21 Aug–1 Nov
2009
11 Jan–10 Mar
2010
18 Jul–8 Sep
2009
13 Feb–6 Apr
2009
28 Feb–6 May
2009
Number of ACTwatch Outlet Survey clusters used to form terminal
wholesaler sampling frame (over the total number of clusters)
19/19 20/38 32/76 20/76 38/38 38/38
Number of wholesalers identified through supplier mentions for the
quantitative survey
228 141 179 213 170 57
- Number of refusals 10 5 0 27 4 1
- Number of duplicates 0 18 18 8 28 0
- Number not eligible 1 9 1 5 1 9
- Number not found 10 10 11 19 2 1
- Number not interviewed for other reasons 3 4 10 14 6 2
Number of quantitative wholesaler interviews conducted 204* 95 139 140 129 44
Number of antimalarials audited 1529 230 1962 2600 1326 288
Number of qualitative in-depth interviews conducted 33 43 36 39 45 42
*Results from Benin are weighted to adjust for over- or under-sampling that may have occurred due to the high number of wholesalers operating within traditional
markets.
doi:10.1371/journal.pone.0093763.t002
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attempts, the business had closed down or moved to an unknown
location). Across the six study countries, we conducted a total of
751 quantitative wholesaler interviews, audited 7935 antimalarial
products, and conducted 238 in-depth interviews (Table 2). The
first three sections below present findings on the overall structure
and other characteristics of the antimalarial distribution chain in
each country, followed by two sections describing wholesaler
practices related to product and supplier choice, and the final
section examines regulation of the wholesale pharmaceutical
sector.
Distribution Chain Structure and Supplier Interactions
As expected, the antimalarial distributions chains in each
country had a pyramidal shape with many wholesalers supplying
retailers at the bottom of the chain and fewer businesses importing
or purchasing antimalarials directly from domestic manufacturers.
Wholesalers performed distinct functions in the chain: those selling
directly to retailers (i.e. terminal wholesalers), those selling to other
wholesalers (e.g. intermediate-1 wholesalers supplying terminal
wholesalers), and those who imported and/or manufactured
antimalarials (i.e. top-level/primary wholesalers). The proportion
of wholesalers that identified a manufacturer as one of their top
two antimalarial supply sources ranged from 5% in Cambodia to
56% in Nigeria (Table 4).
While many wholesalers performed a single function within the
distribution chain (e.g. selling only to retailers), others performed
multiple functions, operating simultaneously on several levels
within the chain (e.g. sold directly to retailers and other
wholesalers). Figure 1 conveys the complexity of these supplier
relationships within the private sector distribution chain by
illustrating the antimalarial supplier-customer interactions docu-
mented as part of the ‘bottom-up’ sampling approach in each
country. In the figure, each dot represents a group of wholesalers
that supply businesses operating at other levels the distribution
chain (each of these levels is represented by a labelled box). The
array of arrows emanating from each dot shows the specific levels
each wholesaler group serves, with some groups of wholesalers
serving multiple levels and others serving only one level. For
example, more than 80% of wholesalers in all countries except
Nigeria sold antimalarials directly to retailers; however the
proportion of wholesalers supplying retailers only ranged consid-
erably across countries, from 30% of wholesalers in Benin to 81%
in Zambia. In contrast, the proportion of wholesalers only
supplying other wholesalers was highest in Nigeria (37%) and
lowest in Zambia (0%). These schematics also suggest that the
maximum number of steps antimalarials could pass through
between manufacturer and retailer ranges from 4 (Cambodia) to 6
(DRC and Uganda); however, the supplier dynamics and
complexities described above indicate that most private sector
antimalarials in the study countries were likely to pass through
only 2 to 3 steps from production to retail.
Intersectoral transactions where private sector wholesalers
identified public or non-governmental medicine distributors as
important sources of antimalarials were observed in most
countries. However, these types of transactions were not common,
apart from in Benin where the national procurement agent,
Centrale d’Achat des Me´dicaments Essentiels et consommables me´dicaux
(CAME), was mentioned by 9.2% of all wholesalers interviewed as
one of their top two antimalarial supply sources. Such private
sector supply transactions are within the remit of CAME.
There was considerable variation in the role of domestic
manufacturers of antimalarials across the countries. Some had
vibrant domestic pharmaceutical sectors: there were over 100
licensed antimalarial manufacturers in Nigeria in 2008, 22 in the
DRC, and 11 in Uganda, producing a diverse array of
antimalarials, including ACTs, though none of these ACTs were
prequalified by the World Health Organization at the time of data
collection. In contrast, there were fewer than 4 manufacturers in
each of the remaining study countries, producing only a handful of
antimalarial products, none of which were ACTs.
Traditional Markets
In Benin, Cambodia and Nigeria, traditional ‘‘open air’’
markets located in commercial cities and towns were important
sources of antimalarial supplies for private sector retailers and
wholesalers. For example, 67% of all supplier mentions gathered
from retailers in Benin, and 55% in Nigeria referred to wholesalers
based in traditional markets. Wholesalers in Benin and Nigeria
also reported market-based businesses as important supply sources,
but this was more prominent in Benin where 60% of all
wholesalers surveyed counted at least one market-based supplier
among their top two antimalarial supply sources.
There were some differences across countries in these markets
and the antimalarial wholesalers operating within them, particu-
larly when comparing Nigeria and Benin. In both countries,
antimalarial wholesaling took place in the key traditional markets
located in national and regional commercial hubs (Lagos, Onitsha
and Kano in Nigeria; Cotonou and Porto Novo in Benin), where
wholesalers tended to operate out of permanent buildings within
the market, but also often maintained off-site warehouse facilities.
Antimalarial wholesaling was also observed to take place in many
smaller traditional markets in smaller city and town centres. In
Benin, these wholesale businesses were sometimes observed to
operate out of less permanent structures (e.g. market stalls) and
traded often only on specific market days, while in Nigeria
comparable wholesalers tended to operate out of permanent
buildings. This is because in Nigeria most of these market-based
wholesalers were operating as drug stores/PPMVs, while in Benin
all market-based wholesalers were completely unlicensed (see
section on regulation below).
Wholesaler Sales Volumes
During in-depth interviews with wholesalers in African coun-
tries, antimalarials were cited as top selling products out of all
types of medicines for many wholesalers and were key revenue
generators. Antimalarial sales volumes among African wholesalers
were overwhelmingly dominated by the sale of nATs, such as
chloroquine, quinine and SP, ranging from a median of 222
AETDs sold during the week preceding the survey in Benin to 563
AETDs in Nigeria. Sales volumes of nATs were many times larger
than those for ACTs, which ranged from a weekly median of 0
AETDs in Benin to 138 AETDs in Nigeria. This is in stark
contrast with the very low wholesaler antimalarial volumes in
Cambodia, where antimalarials were a much smaller part of
overall turnover, and the median weekly sales volume was 2
AETDs for ACTs and 0 AETDs for nATs. Non-negligible weekly
median sales of AMTs were only observed among wholesalers in
the DRC (8 AETDs), Nigeria (42 AETDs) and Uganda (15
AETDs), most of which were sold in banned oral dosage forms
(Table 3). Based on recorded sales volumes, nAT products were
the top-selling antimalarial for more than 60% of wholesalers in
African countries, while the recommended first-line ACT was the
top-selling antimalarial among 57% of Cambodian wholesalers.
Choice of Product
Insight gained about wholesaler product selection during
qualitative interviews helps to explain some of this disparity in
ACT and nAT sales volumes. In all countries, consumer demand
Private Sector Antimalarial Distribution Chains
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was the principal consideration for wholesalers when selecting
products to stock as this affected demand at all levels of the
distribution chain. Wholesalers believed that consumer demand, in
turn, was affected by several key factors, including affordability in
the African study countries and popular perceptions of a
medicine’s quality and efficacy in all countries. In all countries
but Zambia, wholesalers’ concerns about quality and efficacy were
coupled with concerns about the degree of counterfeit and
substandard medicines perceived to be circulating within the
national market.
In Cambodia, popular opinion about the recommended first-
line ACT product’s efficacy was said to be positively affected by
ongoing social marketing campaigns; however, perceived side
effects of the mefloquine component of ASMQ were also believed
to limit consumer demand. This concern about side effects was
also voiced by many wholesalers in the DRC regarding the
amodiaquine component of ASAQ. In Uganda and Zambia, some
wholesalers decided not to stock the recommended first-line
treatment, particularly the brand Coartem, because it was being
offered free of charge in government facilities, reducing consumer
demand for these products in the private sector. However, the
frequency of Coartem stock outs in the Zambian public sector
supply chain led some private wholesalers supplying public sector
customers (e.g. district hospitals) to stock this product. Poor or
irregular availability of first-line drugs among suppliers also
affected wholesaler stocking decisions. Factors affecting availability
reported in Nigeria included shortages of the active pharmaceu-
tical ingredients to manufacture ACTs, delays in importation (e.g.
for clearance of consignments), exchange rate volatility, fuel
shortages, supplier difficulty in maintaining delivery vehicles, and
issues with the couriers contracted to deliver orders.
In all countries apart from Benin, stocking decisions at higher
levels of the distribution chain were constrained by exclusive
distribution rights granted by foreign manufacturers to selected
importers, particularly for ACTs. To qualify for such rights,
importers are often required to register the foreign manufacturer’s
products with the regulatory authorities for introduction to the
market (e.g. conduct product analyses and obtain certificates of
compliance) and also house local sales and/or medical represen-
tatives (i.e. embedded sales force) who actively promote the
manufacturer’s products to prescribers, pharmacists and pharma-
ceutical businesses.
Choice of Supplier
In this section, we present results related to what businesses
consider when selecting suppliers, and supplier strategies for
attracting customers. Among the factors affecting choice of
antimalarial supplier cited by wholesalers, selling price was a key
consideration in most countries. Other common factors related to
a supplier’s reputation for being knowledgeable about medicines
or for selling quality medicines; whether a supplier reliably stocked
a sufficient range of products to fill entire orders; and whether
suppliers offered promotions or discounts. In all countries,
wholesalers provided discounts for orders of larger volume or
value, and wholesalers in Benin also described giving discounts to
customers paying in cash rather than with credit. A number of
respondents in the DRC described giving gifts to customers at the
end of the year such as pens, calendars, free samples, or
appliances, typically related to the total annual value of a
customer’s purchase.
Offering credit was another key means by which wholesalers
attracted customers; however, the availability of supplier credit
varied considerably across the study countries, ranging from just
over a third of wholesalers in Cambodia and the DRC, to about
half in Benin, and more than two-thirds in Nigeria, Uganda and
Zambia (Table 4). Median credit terms ranged from 2 to 4 weeks
across all countries. Credit facilities were often only extended to
long-term customers and the terms could depend on factors such
as past repayment history. As such, it was uncommon for
wholesalers to rely entirely on credit to finance their stocking,
with most using a combination of cash and credit, or cash alone.
Convenience was also a common consideration when choosing
a supplier, related both to proximity and whether or not a supplier
offered delivery services for orders. The proportion of wholesalers
who reported delivering orders to customers varied widely, from a
high of around two-thirds of wholesalers in Zambia, to less than a
third in other countries, and only 8% in Benin (Table 4), reflecting
the small scale nature of the market vendors in Benin. To
illustrate, wholesalers in Benin had a median of 2 staff members
[IQR 2–4], while Zambian wholesalers were considerably larger
with a median of 8 staff members [IQR 5–15] (Table 4). In
Nigeria, Uganda and Zambia, many wholesalers said they were
only willing to deliver to customers located nearby.
Wholesalers operating at higher levels of the distribution chain
described a range of strategies to reach clients further afield and to
increase their market share. In addition to using their own
vehicles, wholesalers described engaging couriers and private mass
transport companies, such as bus operators in Nigeria and
Uganda, to deliver orders to customers. One such method
common in Nigeria is called way billing, where orders placed by
customers are packed by the supplier and transported via mass
transit operators (e.g. bus lines) to regional transport hubs, such as
bus or taxi parks in commercial centres, from where the customer
will retrieve their packaged order.
Sales representatives deployed nationwide to conduct marketing
activities and to take and deliver customer orders were commonly
used by importers and manufacturers. Vertically integrated supply
chains were also encountered in Benin, DRC, Nigeria and
Uganda where a drug manufacturer or importer distributed stock
from a central warehouse to one or more regional warehouses or
wholesale businesses owned by a single enterprise. In Nigeria, a
hybrid model was observed, where some domestic manufacturers
and importers set up similar distribution nodes by contracting
warehousing and distribution services offered by specialised
logistics firms.
Figure 1. Representation of the antimalarial distribution chain illustrating the types of supplier interactions documented by
country. N: number of wholesalers with documented supplier interactions; WS: wholesaler; INT: intermediate. The shaded boxes represent the
different levels of the distribution chain at which wholesalers operate, and the size of each box gives an impression of the proportion of wholesalers
operating at each level. The dots represent mutually exclusive groups of wholesalers that are defined by the specific levels each wholesaler group
serves. This is reflected in the array of arrows emanating from each dot, which illustrates that some wholesaler groups supply several distribution
chain levels and others supply only one level. The percentages attached to each dot give the relative size of each wholesaler group. The dashed line
from manufacturer to retailer indicates that while some retailers purchased antimalarials directly from manufacturers, it was an uncommon practice.
Note that these schematics were constructed using information about the top two antimalarial supply sources mentioned by respondents, and
therefore reflect the most important supplier interactions occurring within the antimalarial distribution chain, rather than all possible interactions or
the volumes of antimalarials flowing through the chain.
doi:10.1371/journal.pone.0093763.g001
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Regulation of the Wholesale Pharmaceutical Sector
During the quantitative survey of wholesalers, we documented
compliance to a limited number of regulatory requirements that
could be easily assessed (Table 5). In all countries, nearly all
wholesalers interviewed were observed to store antimalarials
appropriately, meaning in dry areas, out of direct sunlight and
off the floor. More than 90% of wholesalers in the DRC, Uganda
and Zambia also reported employing at least one member of staff
with health-related qualifications, most commonly pharmacists,
nurses and midwives; compared to Cambodia and Nigeria where
two-thirds of wholesalers reported doing so, and only 29% in
Benin.
There were also marked differences in the number of
wholesalers observed to possess any type of valid licence from
the national pharmaceutical regulator, ranging from a high of
82% of wholesalers in Uganda to a low of 1% in Benin. However,
in all countries fewer wholesalers were observed to have a valid
licence specifically permitting the wholesale of pharmaceuticals.
For example, 15% of wholesale businesses in Zambia were
operating under a retail or OTC medicines licence; and in Nigeria
only 8% of businesses wholesaling antimalarials possessed the
required licence to do so, and another 20% reported having only a
drug shop/PPMV licence. The large majority of wholesalers in all
countries apart from Benin reported that they had been visited by
an inspector at least once during the preceding 12 months.
Qualitative investigations revealed a number of common
themes around low levels of wholesale licensing compliance.
Respondents identified several barriers to obtaining a wholesale
pharmaceutical licence, including relatively high administrative
fees, difficulties in finding an available and affordable supervising
pharmacist, and unclear or overly bureaucratic processes. In
several countries, respondents also described corruption as another
means to circumvent licensing requirements. For example in the
DRC, a few respondents cited instances where unlicensed
businesses threatened with forced closure were permitted to
continue operating following unofficial payments to regulatory
officials. Low levels of enforcement were often attributed to limited
resources within national pharmaceutical regulators, where
inadequate numbers of inspectors and resources for drug quality
testing at points all along the distribution chain restricted the
regulator’s capacity to monitor business activity regularly in all
parts of the country and continually risked compromising the
integrity of the quality assurance chain in the private sector. For
example, one large market vendor in Benin cited the ease of
accessing comparatively cheaper suppliers in Lagos as the main
reason why many vendors in Porto Novo imported illegally. This
respondent went on to describe making smaller purchases more
frequently when restocking in Nigeria to minimise losses if caught
importing illegally; and also transporting stock in a separate
vehicle when returning from Lagos to avoid getting apprehended
with the illegal goods.
In Cambodia and Nigeria, several respondents suggested that
the national regulatory agencies had recently renewed their efforts
to improve compliance and reduce the number of unlicensed
businesses. Wholesalers in all countries also described their
strategies to survive within these complex and sometimes uncertain
regulatory environments, such as by building trustworthy supplier
relationships to help guarantee product quality and authenticity,
or by cooperating with other similar businesses in a number of
ways. In Benin, Nigeria, Uganda and Zambia, trade associations
organised by activity (e.g. importers, drug shops) or jurisdiction
(e.g. specific market or town, national level) provided member
benefits such as assistance in achieving and maintaining regulatory
compliance; information and training on new regulations, policies
and products; access to pooled procurement facilities; and
collective representation of members against regulators and policy
makers. In Benin and Nigeria, associations of drug vendors
operating within traditional markets also performed quasi-regula-
tory functions by providing members with guidance on the
identification and reporting of counterfeit products, and in Benin,
conducting surveys of vendors for expired, banned and other
substandard products, and imposing penalties on offending
businesses.
Discussion
Our study has produced new nationally representative evidence
on the range and extent of interactions among agents working
within a pyramidal antimalarial distribution chain, and on the
characteristics and practices of the businesses that comprise these
chains in each of the study countries. These findings make a
substantial contribution to the limited evidence base around
distribution chains [4]. In addition to furthering understanding of
the complexity of these networks, this new evidence also provides
insight into how factors related to regulation, the broader economy
and consumer culture shape the market for antimalarial drugs.
The study also has important implications for policies and
interventions aiming to improve private sector availability,
affordability and quality of ACTs [29].
Wholesalers identified consumer demand as the primary
determinant of product selection, with the implication that the
high prices of ACTs relative to older, less efficacious antimalarials,
such as chloroquine and SP, not only impede affordability, but are
also a significant barrier to their more widespread availability at
both wholesale and retail levels. This highlights the potential for
subsidies to increase access to ACT in the private sector, as has
been demonstrated by a number of small and large scale subsidy
interventions, including the Affordable Medicines Facility –
malaria (AMFm) [26,30–33], where subsidies increased ACT
market share and improved their availability among retail outlets.
The dominance of consumer demand as a determinant of
product selection also suggests that demand shaping activities,
such as public awareness and social marketing campaigns, are
required to reinforce the effects of price reductions and shift
consumer preferences away from more familiar products. This is
supported by our observations in Cambodia, the only country in
which ACTs dominated wholesaler sales volumes, where ACT
subsidies and consumer demand shaping efforts have been most
vigorously pursued in response to the development of artemisinin
resistance [20]. The need for such supporting interventions for the
success of ACT subsidy programmes was also one of the key
conclusions from the AMFm evaluation [26].
Minimising the number of distribution chain steps that
antimalarials pass through from production to retail level presents
an obvious route to reducing consumer prices. At the time of data
collection, quality assured ACTs (i.e. products certified by the
WHO Prequalification programme) were all imported, unlike
more popular nATs of which most were domestically produced.
Consequently, it is likely that ACTs pass through more steps than
nATs. While building domestic manufacturing capacity for ACTs
could help reduce the steps in the supply chain and achieve price
reductions, some have argued that building such capacity in
malaria endemic countries may not make economic sense because
the conditions required to produce high-quality pharmaceuticals
are not present, even in countries with otherwise highly developed
pharmaceutical sectors [34,35].
Other findings related to drivers of consumer price and barriers
to availability may offer further targets to improve ACT access.
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For instance, the difficulty and additional costs of transporting
goods within countries, particularly in those with large terrains,
poor transportation infrastructure and political instability work to
limit the geographic penetration and affordability of ACTs. This is
particularly the case for quality assured ACTs in those study
countries where exclusive distributors tended to be based in urban
commercial hubs, making it more difficult for wholesalers in more
distant or rural areas to stock ACTs. The range of distribution
models used by larger firms in the DRC, Nigeria and Uganda to
increase their coverage and market share may present some cost-
effective solutions for other settings.
In Benin, Cambodia and the DRC, the limited availability of
credit to finance inventory may indicate that wholesalers,
particularly those at lower levels of the distribution chain, are
constrained from placing larger orders. Because ACTs are
relatively higher priced, smaller wholesalers may not be able to
order in sufficient quantities to benefit from volume-based
discounts or preferred pricing regimes, effectively preventing them
from selling ACTs at more competitive prices. Opportunities to
pool procurement such as those sometimes facilitated through
trade association membership may help to overcome this barrier.
Our findings concerning the low levels of regulatory compliance
and the scale of unauthorized antimalarial wholesaling in several
countries highlight that efforts to improve end-user antimalarial
quality must also account for lapses in quality assurance at
wholesale level. At retail level, many countries have taken a more
pragmatic approach to reduce the number of unauthorized outlets
and improve the quality of pharmaceutical services available to the
public by introducing drug shop licenses (e.g. Class C drug shops
in Uganda, PPMVs in Nigeria) and accreditation initiatives (e.g.
Accredited Drug Dispensing Outlets in Tanzania [36]). In
contrast, little has been done to address the issue of unauthorized
pharmaceutical wholesaling.
Supporting the formation and activities of trade associations
may present a conduit for regulators to engage constructively with
unlicensed wholesalers and act to improve practice standards.
Reducing some barriers to entering the wholesale market may also
help to improve compliance. For example, wholesalers in Benin
are required to maintain an operating capital of 100,000,000 CFA
(US$ 223,215) [37], which is realistically achievable for only very
large firms. Other research suggests that countries with civil (as
opposed to common) legal traditions as a post-colonial legacy are
associated with heavier barriers to entry and consequently have
higher levels of corruption and larger unofficial economies [38].
This may explain some variation in regulatory compliance across
study countries (Benin, the DRC and Cambodia have civil legal
traditions; Nigeria, Uganda and Zambia have common legal
traditions), and understanding the impact of these historical
antecedents may also help in the planning of more effective
regulatory reforms.
Although this study has broadened knowledge on antimalarial
distribution chains and markets, it has also raised additional
questions and highlighted priorities for further research. For
example, efforts to further improve access to malaria treatment
through the private sector will benefit from a better understanding
of wholesaler and retailer antimalarial pricing behaviour. Infor-
mation on different determinants of antimalarial supply and
demand could also help to optimise the impact of subsidies and
other consumer demand shaping activities. To support rational
antimalarial use, it would be useful to investigate how wholesalers
could help increase not only the availability of ACTs at retail level,
but also the availability of diagnostic testing (i.e. RDTs). Finally, it
would also be worthwhile to examine whether our findings related
to antimalarials could be generalised to other pharmaceuticals that
are easily obtained through the private sector, such as antibiotics.
A key limitation of the study relates to the potential sensitivity of
some of the topics, which might contribute to social desirability
bias, with respondents’ answers reflecting what they believe the
interviewer would find acceptable. Also, data from qualitative
interviews were documented using a note taker, rather than being
recorded. While this may have helped to improve the validity of
the data by allowing respondents to be more at ease, some of the
richness and detail of the discourse is likely to have been lost.
Missing supplier information from retail outlets may have also
biased wholesaler sampling frames toward more registered types of
suppliers; however, our innovative ‘bottom-up’ sampling approach
did identify considerable numbers of unregistered wholesalers in
all countries that were included in our samples. Finally, data for
this study were collected in 2009–2010 and changes to the market
since then are likely to have occurred, particularly following the
piloting of the AMFm in Nigeria and Uganda in 2011–2012.
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